ToxiProofAI: Predictive Safety Intelligence for Safer Drug Development

Table of Contents

ToxiProofAI is redefining how drug discovery teams predict, monitor, and mitigate safety risks across the drug development lifecycle.

Built specifically for complex biological therapies, the platform integrates multi-omics, real-world toxicology data, and advanced machine learning to deliver early, actionable insight into potential immune-related adverse events (irAEs) and off-target liabilities. By detecting subtle biological patterns that conventional tools often miss, ToxiProofAI helps researchers design safer modalities, prioritize the right candidates, and avoid costly late-stage surprises.

During clinical development, ToxiProofAI supports patient selection, dose optimization, and early detection of toxicity signals, ultimately de-risking trials and accelerating time to meaningful clinical readouts. By transforming safety assessment from a reactive process into a predictive, data-driven capability, ToxiProofAI empowers organizations to advance innovative drugs, such as IO therapies with greater confidence, speed, and precision.

Picture of Prativa Sinha

Prativa Sinha

Director at Veridon Global Pvt Ltd

Prativa Sinha is a seasoned business strategist with extensive experience in market analysis, innovation, and team leadership. As Director at Veridon Global, she drives operational efficiency and growth while mentoring high-performing teams. With an honors degree in Economics and an MBA in Sales and Marketing, Prativa combines academic expertise with practical leadership to build valuable partnerships and deliver lasting impact.